Athira Pharma, Inc. Stock Price, News & Analysis

Athira Pharma (NASDAQ: ATHA) announced participation in the Jefferies Virtual Healthcare Conference on June 2, 2021, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021. CEO Leen Kawas will engage in a fireside chat and one-on-one investor meetings during these events. Details include the fireside chat at the Jefferies Conference at 4:30 PM ET and the Goldman Sachs Conference at 5:30 PM ET. Webcasts for both events are available on the Athira website, with archived replays accessible for at least 30 days following each event.

Athira Pharma, Inc. (NASDAQ: ATHA) reported financial results for Q1 2021, highlighting a net loss of $8.9 million, or $0.25 per share. The company's cash position improved to $357.7 million following a successful follow-on public offering, raising $103.5 million. Athira is advancing its clinical trials for ATH-1017 in treating Alzheimer’s and Parkinson’s disease dementia, with Phase 2 trials expected to start by late 2021. The company remains focused on developing small molecules aimed at neurodegeneration, maintaining a clear strategic plan and ample funding for future milestones.

Athira Pharma (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company, announced that CEO Leen Kawas, Ph.D., will participate in the Sachs 4th Annual Neuroscience Innovation Forum on April 28, 2021, at 8:30 a.m. PT. The panel titled “Progress in Alzheimer’s and Dementia” will focus on advancements in treating neurodegenerative diseases. The event will also feature notable experts from AZTherapies, NIH, Johnson & Johnson Innovation, and more. A recording will be available starting May 26, and further details can be found on Athira's website.

Athira Pharma (NASDAQ: ATHA) is hosting a webinar on April 15, 2021, at 1:30 p.m. PT to discuss its therapeutic approach targeting the HGF/MET pathway for neurodegeneration. Led by neurologist Marwan Sabbagh, M.D., the session will cover Alzheimer’s and dementia treatment landscapes and the role of hepatocyte growth factor in brain health. Kevin Church, Ph.D., will provide insights on Athira's lead candidate, ATH-1017, designed to enhance HGF/MET activity. Registration is available on Athira’s investor website, and a replay will be accessible for 30 days post-event.

Athira Pharma reported significant developments in its clinical trials and financial status as of March 25, 2021. The company is actively enrolling patients in LIFT-AD and ACT-AD studies for its investigational drug ATH-1017, aimed at treating Alzheimer’s disease. Notably, Athira raised $103.5 million in a follow-on public offering. Financially, the net loss for 2020 was $19.9 million, with cash reserves of $268.2 million expected to sustain operations through at least 2022. The firm anticipates IND submissions for Parkinson’s disease dementia and neuropsychiatric programs by the end of 2021.

Athira Pharma (NASDAQ: ATHA), a biopharmaceutical company focused on neuronal health, announced that its CEO, Leen Kawas, will participate in a virtual fireside chat at Stifel’s 3rd Annual CNS Conference on April 1, 2021, at 9:00 am ET. The event will be accessible via a live webcast on Athira's investor relations website, with an archived replay available for 90 days post-event. Athira is advancing its lead candidate, ATH-1017, targeting Alzheimer's and Parkinson's dementia, aiming to alter the course of neurological diseases and enhance cognitive abilities.

Athira Pharma (NASDAQ: ATHA) will participate in the virtual Life Science Innovation Northwest Conference on March 30-31, 2021. CEO Leen Kawas will discuss new treatments for Alzheimer's disease and neurodegeneration in a panel at 12:30 p.m. PT on March 30, moderated by Paul Matteis. Kevin Church will present a corporate overview from 1:35 to 3:00 p.m. PT on the same day. Both events will be webcast live. Athira is focused on developing small molecules like ATH-1017 to restore neuronal health and combat neurodegeneration.

Athira Pharma (NASDAQ: ATHA) has appointed Barbara Kosacz to its Board of Directors. Kosacz, COO and General Counsel at Kronos Bio, brings over 25 years of experience in life sciences, having led significant transactions in the industry. CEO Leen Kawas emphasized her expertise will enhance the Board's capabilities as Athira progresses with its clinical trials. Kosacz expressed enthusiasm for Athira's novel drug development platform aimed at treating neurological diseases like Alzheimer's and Parkinson's. Athira continues to advance its lead candidate, ATH-1017.

Athira Pharma (NASDAQ: ATHA) will present a corporate overview at the H.C. Wainwright & Co. Global Life Sciences Conference. Leen Kawas, Ph.D., President and CEO, will lead the pre-recorded presentation available at 7:00 am ET on March 9, 2021. The presentation can be accessed on-demand through the Athira website, with an archived replay available for 90 days post-event. Athira focuses on developing small molecules to restore neuronal health, targeting Alzheimer’s and Parkinson’s dementia with its lead candidate, ATH-1017.